PMC:7600245 / 52738-54153 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T236","span":{"begin":1110,"end":1113},"obj":"Body_part"}],"attributes":[{"id":"A236","pred":"fma_id","subj":"T236","obj":"http://purl.org/sig/ont/fma/fma24890"}],"text":"Famotidine is a synthetic guandino-thiazole derivative (Figure 7) that acts as a potent and competitive H2-blocker. It was first approved by the U.S. FDA in 1986 and now is used as over-the-counter drug. It can be used orally or parenterally to treat gastroesophageal reflux disease, heartburn, and peptic ulcer [166]. Recently, a retrospective non-randomized study by Columbia University, Northwell Health, and Massachusetts General Hospital showed that famotidine, and not proton pump inhibitors, reduced the risk of intubation or death in hospitalized COVID-19 patients (n = 84) [167]. Furthermore, a case series indicated that COVID-19 patients (n = 10) who frequently self-administered a high-dose of oral famotidine (most frequent dose was 80 mg three times/day for a median of 11 days) reported significant symptoms improvement within 24 hours of starting famotidine [168]. Therefore, intravenously administered famotidine with standard of care (orally administered hydroxychloroquine and has progressed to include remdesivir) is currently being studied in a multi-site, randomized, double-blind, multi-arm historical control, comparative trial that is sponsored by Northwell Health, New York (NCT04370262; n = 942). Famotidine has been identified via virtual screening and molecular modeling, docking, and scoring as a potential inhibitor of Mpro [169], yet this potential is to be experimentally confirmed."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T20","span":{"begin":1110,"end":1113},"obj":"Body_part"}],"attributes":[{"id":"A20","pred":"uberon_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/UBERON_0001460"}],"text":"Famotidine is a synthetic guandino-thiazole derivative (Figure 7) that acts as a potent and competitive H2-blocker. It was first approved by the U.S. FDA in 1986 and now is used as over-the-counter drug. It can be used orally or parenterally to treat gastroesophageal reflux disease, heartburn, and peptic ulcer [166]. Recently, a retrospective non-randomized study by Columbia University, Northwell Health, and Massachusetts General Hospital showed that famotidine, and not proton pump inhibitors, reduced the risk of intubation or death in hospitalized COVID-19 patients (n = 84) [167]. Furthermore, a case series indicated that COVID-19 patients (n = 10) who frequently self-administered a high-dose of oral famotidine (most frequent dose was 80 mg three times/day for a median of 11 days) reported significant symptoms improvement within 24 hours of starting famotidine [168]. Therefore, intravenously administered famotidine with standard of care (orally administered hydroxychloroquine and has progressed to include remdesivir) is currently being studied in a multi-site, randomized, double-blind, multi-arm historical control, comparative trial that is sponsored by Northwell Health, New York (NCT04370262; n = 942). Famotidine has been identified via virtual screening and molecular modeling, docking, and scoring as a potential inhibitor of Mpro [169], yet this potential is to be experimentally confirmed."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T229","span":{"begin":251,"end":282},"obj":"Disease"},{"id":"T230","span":{"begin":299,"end":311},"obj":"Disease"},{"id":"T231","span":{"begin":306,"end":311},"obj":"Disease"},{"id":"T232","span":{"begin":555,"end":563},"obj":"Disease"},{"id":"T233","span":{"begin":631,"end":639},"obj":"Disease"}],"attributes":[{"id":"A229","pred":"mondo_id","subj":"T229","obj":"http://purl.obolibrary.org/obo/MONDO_0007186"},{"id":"A230","pred":"mondo_id","subj":"T230","obj":"http://purl.obolibrary.org/obo/MONDO_0004247"},{"id":"A231","pred":"mondo_id","subj":"T231","obj":"http://purl.obolibrary.org/obo/MONDO_0043839"},{"id":"A232","pred":"mondo_id","subj":"T232","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A233","pred":"mondo_id","subj":"T233","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Famotidine is a synthetic guandino-thiazole derivative (Figure 7) that acts as a potent and competitive H2-blocker. It was first approved by the U.S. FDA in 1986 and now is used as over-the-counter drug. It can be used orally or parenterally to treat gastroesophageal reflux disease, heartburn, and peptic ulcer [166]. Recently, a retrospective non-randomized study by Columbia University, Northwell Health, and Massachusetts General Hospital showed that famotidine, and not proton pump inhibitors, reduced the risk of intubation or death in hospitalized COVID-19 patients (n = 84) [167]. Furthermore, a case series indicated that COVID-19 patients (n = 10) who frequently self-administered a high-dose of oral famotidine (most frequent dose was 80 mg three times/day for a median of 11 days) reported significant symptoms improvement within 24 hours of starting famotidine [168]. Therefore, intravenously administered famotidine with standard of care (orally administered hydroxychloroquine and has progressed to include remdesivir) is currently being studied in a multi-site, randomized, double-blind, multi-arm historical control, comparative trial that is sponsored by Northwell Health, New York (NCT04370262; n = 942). Famotidine has been identified via virtual screening and molecular modeling, docking, and scoring as a potential inhibitor of Mpro [169], yet this potential is to be experimentally confirmed."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T534","span":{"begin":14,"end":15},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T535","span":{"begin":79,"end":80},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T536","span":{"begin":329,"end":330},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T537","span":{"begin":602,"end":603},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T538","span":{"begin":691,"end":692},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T539","span":{"begin":772,"end":773},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T540","span":{"begin":784,"end":786},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T541","span":{"begin":996,"end":999},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T542","span":{"begin":1064,"end":1065},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T543","span":{"begin":1110,"end":1113},"obj":"http://www.ebi.ac.uk/efo/EFO_0001410"},{"id":"T544","span":{"begin":1235,"end":1238},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T545","span":{"begin":1325,"end":1326},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Famotidine is a synthetic guandino-thiazole derivative (Figure 7) that acts as a potent and competitive H2-blocker. It was first approved by the U.S. FDA in 1986 and now is used as over-the-counter drug. It can be used orally or parenterally to treat gastroesophageal reflux disease, heartburn, and peptic ulcer [166]. Recently, a retrospective non-randomized study by Columbia University, Northwell Health, and Massachusetts General Hospital showed that famotidine, and not proton pump inhibitors, reduced the risk of intubation or death in hospitalized COVID-19 patients (n = 84) [167]. Furthermore, a case series indicated that COVID-19 patients (n = 10) who frequently self-administered a high-dose of oral famotidine (most frequent dose was 80 mg three times/day for a median of 11 days) reported significant symptoms improvement within 24 hours of starting famotidine [168]. Therefore, intravenously administered famotidine with standard of care (orally administered hydroxychloroquine and has progressed to include remdesivir) is currently being studied in a multi-site, randomized, double-blind, multi-arm historical control, comparative trial that is sponsored by Northwell Health, New York (NCT04370262; n = 942). Famotidine has been identified via virtual screening and molecular modeling, docking, and scoring as a potential inhibitor of Mpro [169], yet this potential is to be experimentally confirmed."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T2013","span":{"begin":35,"end":43},"obj":"Chemical"},{"id":"T78712","span":{"begin":104,"end":106},"obj":"Chemical"},{"id":"T92725","span":{"begin":198,"end":202},"obj":"Chemical"},{"id":"T27956","span":{"begin":455,"end":465},"obj":"Chemical"},{"id":"T55138","span":{"begin":475,"end":497},"obj":"Chemical"},{"id":"T68332","span":{"begin":475,"end":481},"obj":"Chemical"},{"id":"T72811","span":{"begin":487,"end":497},"obj":"Chemical"},{"id":"T96455","span":{"begin":711,"end":721},"obj":"Chemical"},{"id":"T73357","span":{"begin":863,"end":873},"obj":"Chemical"},{"id":"T69341","span":{"begin":919,"end":929},"obj":"Chemical"},{"id":"T6716","span":{"begin":973,"end":991},"obj":"Chemical"},{"id":"T50648","span":{"begin":1022,"end":1032},"obj":"Chemical"},{"id":"T31143","span":{"begin":1337,"end":1346},"obj":"Chemical"}],"attributes":[{"id":"A72545","pred":"chebi_id","subj":"T2013","obj":"http://purl.obolibrary.org/obo/CHEBI_43732"},{"id":"A6280","pred":"chebi_id","subj":"T2013","obj":"http://purl.obolibrary.org/obo/CHEBI_48901"},{"id":"A43228","pred":"chebi_id","subj":"T78712","obj":"http://purl.obolibrary.org/obo/CHEBI_18276"},{"id":"A14435","pred":"chebi_id","subj":"T92725","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A67602","pred":"chebi_id","subj":"T27956","obj":"http://purl.obolibrary.org/obo/CHEBI_4975"},{"id":"A96935","pred":"chebi_id","subj":"T55138","obj":"http://purl.obolibrary.org/obo/CHEBI_49200"},{"id":"A40903","pred":"chebi_id","subj":"T68332","obj":"http://purl.obolibrary.org/obo/CHEBI_24636"},{"id":"A42223","pred":"chebi_id","subj":"T72811","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A86700","pred":"chebi_id","subj":"T96455","obj":"http://purl.obolibrary.org/obo/CHEBI_4975"},{"id":"A82288","pred":"chebi_id","subj":"T73357","obj":"http://purl.obolibrary.org/obo/CHEBI_4975"},{"id":"A87304","pred":"chebi_id","subj":"T69341","obj":"http://purl.obolibrary.org/obo/CHEBI_4975"},{"id":"A41136","pred":"chebi_id","subj":"T6716","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A99139","pred":"chebi_id","subj":"T50648","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A74432","pred":"chebi_id","subj":"T31143","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"Famotidine is a synthetic guandino-thiazole derivative (Figure 7) that acts as a potent and competitive H2-blocker. It was first approved by the U.S. FDA in 1986 and now is used as over-the-counter drug. It can be used orally or parenterally to treat gastroesophageal reflux disease, heartburn, and peptic ulcer [166]. Recently, a retrospective non-randomized study by Columbia University, Northwell Health, and Massachusetts General Hospital showed that famotidine, and not proton pump inhibitors, reduced the risk of intubation or death in hospitalized COVID-19 patients (n = 84) [167]. Furthermore, a case series indicated that COVID-19 patients (n = 10) who frequently self-administered a high-dose of oral famotidine (most frequent dose was 80 mg three times/day for a median of 11 days) reported significant symptoms improvement within 24 hours of starting famotidine [168]. Therefore, intravenously administered famotidine with standard of care (orally administered hydroxychloroquine and has progressed to include remdesivir) is currently being studied in a multi-site, randomized, double-blind, multi-arm historical control, comparative trial that is sponsored by Northwell Health, New York (NCT04370262; n = 942). Famotidine has been identified via virtual screening and molecular modeling, docking, and scoring as a potential inhibitor of Mpro [169], yet this potential is to be experimentally confirmed."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T51","span":{"begin":251,"end":282},"obj":"Phenotype"},{"id":"T52","span":{"begin":284,"end":293},"obj":"Phenotype"},{"id":"T53","span":{"begin":299,"end":311},"obj":"Phenotype"}],"attributes":[{"id":"A51","pred":"hp_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/HP_0002020"},{"id":"A52","pred":"hp_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/HP_0002020"},{"id":"A53","pred":"hp_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/HP_0004398"}],"text":"Famotidine is a synthetic guandino-thiazole derivative (Figure 7) that acts as a potent and competitive H2-blocker. It was first approved by the U.S. FDA in 1986 and now is used as over-the-counter drug. It can be used orally or parenterally to treat gastroesophageal reflux disease, heartburn, and peptic ulcer [166]. Recently, a retrospective non-randomized study by Columbia University, Northwell Health, and Massachusetts General Hospital showed that famotidine, and not proton pump inhibitors, reduced the risk of intubation or death in hospitalized COVID-19 patients (n = 84) [167]. Furthermore, a case series indicated that COVID-19 patients (n = 10) who frequently self-administered a high-dose of oral famotidine (most frequent dose was 80 mg three times/day for a median of 11 days) reported significant symptoms improvement within 24 hours of starting famotidine [168]. Therefore, intravenously administered famotidine with standard of care (orally administered hydroxychloroquine and has progressed to include remdesivir) is currently being studied in a multi-site, randomized, double-blind, multi-arm historical control, comparative trial that is sponsored by Northwell Health, New York (NCT04370262; n = 942). Famotidine has been identified via virtual screening and molecular modeling, docking, and scoring as a potential inhibitor of Mpro [169], yet this potential is to be experimentally confirmed."}

{"project":"LitCovid-sentences","denotations":[{"id":"T393","span":{"begin":0,"end":115},"obj":"Sentence"},{"id":"T394","span":{"begin":116,"end":149},"obj":"Sentence"},{"id":"T395","span":{"begin":150,"end":203},"obj":"Sentence"},{"id":"T396","span":{"begin":204,"end":318},"obj":"Sentence"},{"id":"T397","span":{"begin":319,"end":588},"obj":"Sentence"},{"id":"T398","span":{"begin":589,"end":880},"obj":"Sentence"},{"id":"T399","span":{"begin":881,"end":1223},"obj":"Sentence"},{"id":"T400","span":{"begin":1224,"end":1415},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Famotidine is a synthetic guandino-thiazole derivative (Figure 7) that acts as a potent and competitive H2-blocker. It was first approved by the U.S. FDA in 1986 and now is used as over-the-counter drug. It can be used orally or parenterally to treat gastroesophageal reflux disease, heartburn, and peptic ulcer [166]. Recently, a retrospective non-randomized study by Columbia University, Northwell Health, and Massachusetts General Hospital showed that famotidine, and not proton pump inhibitors, reduced the risk of intubation or death in hospitalized COVID-19 patients (n = 84) [167]. Furthermore, a case series indicated that COVID-19 patients (n = 10) who frequently self-administered a high-dose of oral famotidine (most frequent dose was 80 mg three times/day for a median of 11 days) reported significant symptoms improvement within 24 hours of starting famotidine [168]. Therefore, intravenously administered famotidine with standard of care (orally administered hydroxychloroquine and has progressed to include remdesivir) is currently being studied in a multi-site, randomized, double-blind, multi-arm historical control, comparative trial that is sponsored by Northwell Health, New York (NCT04370262; n = 942). Famotidine has been identified via virtual screening and molecular modeling, docking, and scoring as a potential inhibitor of Mpro [169], yet this potential is to be experimentally confirmed."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1656","span":{"begin":1350,"end":1354},"obj":"Gene"},{"id":"1657","span":{"begin":564,"end":572},"obj":"Species"},{"id":"1658","span":{"begin":640,"end":648},"obj":"Species"},{"id":"1659","span":{"begin":0,"end":10},"obj":"Chemical"},{"id":"1660","span":{"begin":26,"end":43},"obj":"Chemical"},{"id":"1661","span":{"begin":104,"end":106},"obj":"Chemical"},{"id":"1662","span":{"begin":455,"end":465},"obj":"Chemical"},{"id":"1663","span":{"begin":711,"end":721},"obj":"Chemical"},{"id":"1664","span":{"begin":863,"end":873},"obj":"Chemical"},{"id":"1665","span":{"begin":919,"end":929},"obj":"Chemical"},{"id":"1666","span":{"begin":973,"end":991},"obj":"Chemical"},{"id":"1667","span":{"begin":1022,"end":1032},"obj":"Chemical"},{"id":"1668","span":{"begin":1224,"end":1234},"obj":"Chemical"},{"id":"1669","span":{"begin":251,"end":282},"obj":"Disease"},{"id":"1670","span":{"begin":299,"end":311},"obj":"Disease"},{"id":"1671","span":{"begin":533,"end":538},"obj":"Disease"},{"id":"1672","span":{"begin":555,"end":563},"obj":"Disease"},{"id":"1673","span":{"begin":631,"end":639},"obj":"Disease"}],"attributes":[{"id":"A1656","pred":"tao:has_database_id","subj":"1656","obj":"Gene:8673700"},{"id":"A1657","pred":"tao:has_database_id","subj":"1657","obj":"Tax:9606"},{"id":"A1658","pred":"tao:has_database_id","subj":"1658","obj":"Tax:9606"},{"id":"A1659","pred":"tao:has_database_id","subj":"1659","obj":"MESH:D015738"},{"id":"A1661","pred":"tao:has_database_id","subj":"1661","obj":"MESH:D003903"},{"id":"A1662","pred":"tao:has_database_id","subj":"1662","obj":"MESH:D015738"},{"id":"A1663","pred":"tao:has_database_id","subj":"1663","obj":"MESH:D015738"},{"id":"A1664","pred":"tao:has_database_id","subj":"1664","obj":"MESH:D015738"},{"id":"A1665","pred":"tao:has_database_id","subj":"1665","obj":"MESH:D015738"},{"id":"A1666","pred":"tao:has_database_id","subj":"1666","obj":"MESH:D006886"},{"id":"A1667","pred":"tao:has_database_id","subj":"1667","obj":"MESH:C000606551"},{"id":"A1668","pred":"tao:has_database_id","subj":"1668","obj":"MESH:D015738"},{"id":"A1669","pred":"tao:has_database_id","subj":"1669","obj":"MESH:D005764"},{"id":"A1670","pred":"tao:has_database_id","subj":"1670","obj":"MESH:D010437"},{"id":"A1671","pred":"tao:has_database_id","subj":"1671","obj":"MESH:D003643"},{"id":"A1672","pred":"tao:has_database_id","subj":"1672","obj":"MESH:C000657245"},{"id":"A1673","pred":"tao:has_database_id","subj":"1673","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Famotidine is a synthetic guandino-thiazole derivative (Figure 7) that acts as a potent and competitive H2-blocker. It was first approved by the U.S. FDA in 1986 and now is used as over-the-counter drug. It can be used orally or parenterally to treat gastroesophageal reflux disease, heartburn, and peptic ulcer [166]. Recently, a retrospective non-randomized study by Columbia University, Northwell Health, and Massachusetts General Hospital showed that famotidine, and not proton pump inhibitors, reduced the risk of intubation or death in hospitalized COVID-19 patients (n = 84) [167]. Furthermore, a case series indicated that COVID-19 patients (n = 10) who frequently self-administered a high-dose of oral famotidine (most frequent dose was 80 mg three times/day for a median of 11 days) reported significant symptoms improvement within 24 hours of starting famotidine [168]. Therefore, intravenously administered famotidine with standard of care (orally administered hydroxychloroquine and has progressed to include remdesivir) is currently being studied in a multi-site, randomized, double-blind, multi-arm historical control, comparative trial that is sponsored by Northwell Health, New York (NCT04370262; n = 942). Famotidine has been identified via virtual screening and molecular modeling, docking, and scoring as a potential inhibitor of Mpro [169], yet this potential is to be experimentally confirmed."}